MCID: MCL006
MIFTS: 55

Macular Retinal Edema

Categories: Cardiovascular diseases, Eye diseases

Aliases & Classifications for Macular Retinal Edema

MalaCards integrated aliases for Macular Retinal Edema:

Name: Macular Retinal Edema 12 15 71
Macular Edema 12 36 54 15
Macular Edema, Cystoid 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4449
KEGG 36 H01651
MeSH 43 D008269
NCIt 49 C35468
SNOMED-CT 67 37231002
UMLS 71 C0024440 C0271051

Summaries for Macular Retinal Edema

KEGG : 36 Macular edema is a common feature of many diseases of the retina, such as intraocular inflammation (uveitis), central or branch retinal vein occlusion, diabetic retinopathy and following cataract extraction. It is characterized by a retinal thickening in the macular area due to the breakdown of the blood-retinal barrier. Extracellular fluid accumulates in the intraretinal area or collects in the subretinal space. In more severe cases, it occurs as cystoid edema with the typical petaloid appearance, and is the leading cause of visual loss. New treatments for macular edema have emerged over the past decade, the most recent and efficacious of which have involved blockage of vascular endothelial growth factor (VEGF) by frequent intravitreal injection of pharmacologic agents.

MalaCards based summary : Macular Retinal Edema, also known as macular edema, is related to diabetic macular edema and vitreoretinopathy, neovascular inflammatory, and has symptoms including edema and peau d'orange. An important gene associated with Macular Retinal Edema is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Acetazolamide and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Macular Retinal Edema

Diseases related to Macular Retinal Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 791)
# Related Disease Score Top Affiliating Genes
1 diabetic macular edema 34.1 VEGFB VEGFA PGF IL6 ICAM1 FLT1
2 vitreoretinopathy, neovascular inflammatory 32.9 VEGFA TJP1 CCL2
3 macular dystrophy, dominant cystoid 32.7 VEGFA MRAP KCNMA1 CRB1 ACE
4 central retinal vein occlusion 32.2 VEGFA PLG IL6
5 uveitis 31.8 TNF IL6 ICAM1 CXCL8 CCL2
6 vitreous detachment 31.7 VEGFB VEGFA PLG KCNMA1
7 retinal vein occlusion 31.6 VEGFA TNF KDR IL6 CXCL8 CCL2
8 retinal detachment 31.6 VEGFA TNF IL6 CXCL8 CCL2
9 neuroretinitis 31.5 MRAP ACE
10 intermediate uveitis 31.5 TNF MRAP IL6
11 posterior uveitis 31.5 TNF MRAP IL6
12 microvascular complications of diabetes 1 31.4 VEGFA INS ICAM1 FLT1 CXCL8 CCL2
13 retinitis pigmentosa 31.3 VEGFA TNF TJP1 MRAP KCNMA1 INS
14 microvascular complications of diabetes 5 31.3 VEGFA PLG PGF KDR INS ICAM1
15 macular holes 31.2 VEGFA PLG KCNMA1 CXCL8 CCL2
16 papilledema 31.2 VEGFA ALB ACE
17 iridocyclitis 31.2 TNF MRAP IL6 ACE
18 lipid metabolism disorder 31.2 INS IL6 CCL2 ACE
19 retinal microaneurysm 31.2 VEGFA INS
20 retinal vasculitis 31.1 MRAP CCL2 ACE
21 panuveitis 31.1 VEGFA TNF MRAP IL6 ACE
22 coats disease 31.1 VEGFA KDR CRB1
23 vasculitis 31.1 TNF IL6 ICAM1 CCL2
24 microvascular complications of diabetes 3 31.0 INS ALB ACE
25 branch retinal artery occlusion 30.9 VEGFA PLG FANCG
26 optic nerve disease 30.9 VEGFA TNF IL6 ALB ACE
27 central retinal artery occlusion 30.9 VEGFA PLG FANCG
28 arteriovenous malformation 30.8 VEGFA TNF IL6
29 cataract 30.8 VEGFA TNF TJP1 INS IL6 ICAM1
30 acquired immunodeficiency syndrome 30.8 TNF IL6 ICAM1 ALB
31 poems syndrome 30.8 VEGFA TNF IL6
32 iritis 30.8 TNF MRAP IL6 ACE
33 keratopathy 30.7 TNF ICAM1 CXCL8
34 syphilis 30.7 MRAP ALB ACE
35 kuhnt-junius degeneration 30.7 VEGFB VEGFA PLG PGF KDR FLT1
36 neuritis 30.7 TNF IL6 CXCL8 CCL2
37 eales disease 30.7 VEGFA TNF IL6
38 sarcoidosis 1 30.7 TNF MRAP ICAM1 CCL2 ACE
39 juvenile rheumatoid arthritis 30.7 TNF IL6 CXCL8 CCL2 ALB
40 scleritis 30.7 TNF MRAP CCL2
41 severe nonproliferative diabetic retinopathy 30.6 VEGFA PGF INS ICAM1 CCL2 ALB
42 end stage renal failure 30.6 TNF IL6 ALB ACE
43 diabetic neuropathy 30.6 VEGFA INS ICAM1 ACE
44 hypertensive retinopathy 30.6 VEGFA FANCG ALB ACE
45 chickenpox 30.5 TNF IL6 ALB
46 chorioretinitis 30.5 VEGFA TNF MRAP IL6 ACE
47 relapsing-remitting multiple sclerosis 30.5 TNF IL6 ICAM1 CXCL8 CCL2
48 cancer-associated retinopathy 30.5 VEGFA PGF FLT1
49 brain edema 30.5 VEGFA TJP1 IL6 ALB
50 background diabetic retinopathy 30.5 VEGFA PGF KDR INS IL6 ICAM1

Graphical network of the top 20 diseases related to Macular Retinal Edema:



Diseases related to Macular Retinal Edema

Symptoms & Phenotypes for Macular Retinal Edema

UMLS symptoms related to Macular Retinal Edema:


edema, peau d'orange

MGI Mouse Phenotypes related to Macular Retinal Edema:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.42 ACE ALB CRB1 FLT1 ICAM1 IL6
2 homeostasis/metabolism MP:0005376 10.38 ACE ALB CRB1 FLT1 ICAM1 IL6
3 cellular MP:0005384 10.35 ALB CRB1 FANCG FLT1 ICAM1 IL6
4 growth/size/body region MP:0005378 10.34 ACE FLT1 ICAM1 IL6 INS KCNMA1
5 immune system MP:0005387 10.3 ACE ALB CCL2 CRB1 FLT1 ICAM1
6 endocrine/exocrine gland MP:0005379 10.29 ACE ALB CRB1 FANCG ICAM1 IL6
7 mortality/aging MP:0010768 10.28 ACE ALB CRB1 FLT1 ICAM1 IL6
8 digestive/alimentary MP:0005381 10.18 ALB ICAM1 IL6 INS KCNMA1 OCLN
9 liver/biliary system MP:0005370 10.09 ACE ALB IL6 INS KDR MRAP
10 muscle MP:0005369 10.07 ALB FLT1 ICAM1 IL6 INS KCNMA1
11 nervous system MP:0003631 10.07 CRB1 FLT1 ICAM1 IL6 INS KCNMA1
12 neoplasm MP:0002006 9.92 ACE ALB ICAM1 IL6 PGF PLG
13 renal/urinary system MP:0005367 9.76 ACE ALB IL6 INS KCNMA1 PLG
14 reproductive system MP:0005389 9.7 ACE FANCG FLT1 IL6 INS KCNMA1
15 vision/eye MP:0005391 9.36 CRB1 FLT1 ICAM1 IL6 INS KDR

Drugs & Therapeutics for Macular Retinal Edema

Drugs for Macular Retinal Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 330)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
4
Linagliptin Approved Phase 4 668270-12-0 10096344
5
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
6
Bevacizumab Approved, Investigational Phase 4 216974-75-3
7
Homatropine Approved Phase 4 87-00-3
8
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
9
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
10
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
11
Travoprost Approved Phase 4 157283-68-6 5282226
12
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
13
Interferon beta-1b Approved Phase 4 145155-23-3
14
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
15
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
16
Bromfenac Approved Phase 4 91714-94-2 60726
17
Pseudoephedrine Approved Phase 4 90-82-4 7028
18
Ephedrine Approved Phase 4 299-42-3 9294
19
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
20
Phenylephrine Approved Phase 4 59-42-7 6041
21
Difluprednate Approved Phase 4 23674-86-4 443936
22
Fluprednisolone Approved Phase 4 53-34-9
23
Verteporfin Approved, Investigational Phase 4 129497-78-5
24
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
25
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
26
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
27
Polyestradiol phosphate Approved Phase 4 28014-46-2
28
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
29
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
30
Fenofibrate Approved Phase 4 49562-28-9 3339
31
Dipivefrin Approved Phase 4 52365-63-6 3105
32
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
33
Povidone-iodine Approved Phase 4 25655-41-8
34
Povidone Approved Phase 4 9003-39-8
35
Iodine Approved, Investigational Phase 4 7553-56-2 807
36
Simvastatin Approved Phase 4 79902-63-9 54454
37
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
38
Ofloxacin Approved Phase 4 82419-36-1 4583
39
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
40
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
41 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
42
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
43
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
44
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
45
leucovorin Approved Phase 4 58-05-9 6006 143
46
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
47
Empagliflozin Approved Phase 4 864070-44-0
48
Glimepiride Approved Phase 4 93479-97-1 3476
49
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001

Interventional clinical trials:

(show top 50) (show all 908)
# Name Status NCT ID Phase Drugs
1 POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
2 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Unknown status NCT03097068 Phase 4 Lucentis
3 Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
4 Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES) Unknown status NCT01857544 Phase 4 Aflibercept
5 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
6 Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study Unknown status NCT02059772 Phase 4 ranibizumab
7 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
8 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
9 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Unknown status NCT02924987 Phase 4 Aflibercept Injection
10 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
11 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
12 To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
13 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
14 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
15 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
16 Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm Unknown status NCT02274259 Phase 4 Aflibercept;Ranibizumab
17 Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema Unknown status NCT03211741 Phase 4 Bevacizumab Injection [Avastin]
18 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
19 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
20 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
21 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
22 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
23 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
24 EFFECTS OF IMMEDIATE ARGON LASER PERIPHERAL IRIDOPLASTY Versus CONVENTIONAL SYSTEMIC MEDICAL THERAPY ON OPTIC NERVE HEAD STRUCTURE AND FUNCTION OF ACUTE PRIMARY ANGLE CLOSURE EYES Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
25 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
26 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
27 Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
28 Evaluation of ReAding Speed, Contrast Sensitivity, and Work Productivity in Working Individuals With Diabetic Macular Edema Following Treatment With Intravitreal Ranibizumab Completed NCT02107131 Phase 4 Intravitreal ranibizumab 0.3mg
29 An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema Completed NCT01297569 Phase 4 Ranibizumab
30 Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab. Completed NCT00801866 Phase 4 Bevacizumab
31 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4 dexamethasone implant
32 Randomized Clinical Trial Comparing Prophylactic Nepafenac 0.1% and Ketorolac 0.5% Versus Placebo in Preventing Postoperative Macular Edema After Uncomplicated Phacoemulsification Cataract Extraction (PNK) Completed NCT01395069 Phase 4 Nepafenac 0.1%;Ketorolac 0.5%
33 A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
34 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy Completed NCT02472366 Phase 4 ILUVIEN
35 Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
36 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
37 An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice Completed NCT01315275 Phase 4 Ranibizumab
38 A Single Masked, Randomized Controlled Study to Assess Efficacy of Ozurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant
39 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
40 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
41 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
42 Central Macular Thickness, Macular Electroretinogram, and Visual Acuity in Patients With Diabetic Macular Edema After Intravitreal Aflibercept Injection. A One Month Pre-Post Intervention Follow Up Study Completed NCT03453281 Phase 4 Aflibercept Injection [Eylea]
43 A 10 Month, Single Masked, Randomized Controlled Study to Assess Anti-VEGF Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
44 A Non-randomised, Open-label, Multicenter Phase 4 Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies With or Without Intravitreal Corticosteroid Therapy (RESPOND) Completed NCT02359526 Phase 4 IlUVIEN
45 Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study) Completed NCT02392364 Phase 4 Intravitreal Aflibercept Injection
46 Dexamethasone Intravitreal Implant (0.7mg) for the Treatment of Persistent Diabetic Macular Edema Following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Completed NCT02471651 Phase 4 Dexamethasone intravitreal implant (0.7 mg);Intravitreal anti-VEGF injection
47 Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion Completed NCT01767545 Phase 4 Dexamethasone implant;Bevacizumab
48 Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5% Completed NCT00595543 Phase 4 Bromfenac;Ketorolac;Diclofenac
49 Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
50 Evaluation of Visual Acuity Improvement of a PRN Regimen Using Ranibizumab for Macular Edema Due to Ischemic and Non- Ischemic Branch Retinal Vein Occlusion. Completed NCT02478515 Phase 4 Ranibizumab

Search NIH Clinical Center for Macular Retinal Edema

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Flurbiprofen
Flurbiprofen sodium

Genetic Tests for Macular Retinal Edema

Anatomical Context for Macular Retinal Edema

MalaCards organs/tissues related to Macular Retinal Edema:

40
Eye, Endothelial, Retina, Bone, Testes, Kidney, Heart

Publications for Macular Retinal Edema

Articles related to Macular Retinal Edema:

(show top 50) (show all 9361)
# Title Authors PMID Year
1
Novel REEP6 gene mutation associated with autosomal recessive retinitis pigmentosa. 61
31538292 2020
2
Guidelines for the prevention and management of diabetic retinopathy and diabetic eye disease in India: A synopsis. 61
31937733 2020
3
Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up. 61
31647931 2020
4
Validation of Deep Convolutional Neural Network-based algorithm for detection of diabetic retinopathy - Artificial intelligence versus clinician for screening. 61
31957737 2020
5
Comparative evaluation of re-use or replacement of dislocated 3-piece intraocular lenses with a scleral fixation technique. 61
31722807 2020
6
Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. 61
32020843 2020
7
[Retinal laser treatment-avoiding mistakes]. 61
32002621 2020
8
The effects of hyperbaric oxygen therapy on diabetic retinopathy: A preliminary study. 61
31831276 2020
9
Spectrum of eye disorders in diabetes (SPEED) in India. Report # 2. Diabetic retinopathy and risk factors for sight threatening diabetic retinopathy in people with type 2 diabetes in India. 61
31937724 2020
10
Cyclophotocoagulation in the Control of Glaucoma in Patients With the Boston Keratoprosthesis Type 1. 61
31335536 2020
11
19th EURETINA Congress Keynote Lecture: Diabetic Retinopathy Today. 61
32015239 2020
12
Rationale, Design, Methodology and Baseline Data of Fushun Diabetic Retinopathy Cohort Study (FS-DIRECT). 61
31722595 2020
13
Medios- An offline, smartphone-based artificial intelligence algorithm for the diagnosis of diabetic retinopathy. 61
31957735 2020
14
RELATIONSHIP BETWEEN ABNORMALITIES OF PHOTORECEPTOR MICROSTRUCTURES AND MICROVASCULAR STRUCTURES DETERMINED BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN EYES WITH BRANCH RETINAL VEIN OCCLUSION. 61
31972806 2020
15
Longitudinal Panretinal Leakage and Ischemic Indices in Retinal Vascular Disease after Aflibercept Therapy: The PERMEATE Study. 61
31757691 2020
16
Prognostic role of optical coherence tomography after switch to dexamethasone in diabetic macular edema. 61
31375899 2020
17
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES AFTER SUBTHRESHOLD MICROPULSE YELLOW LASER IN DIABETIC MACULAR EDEMA. 61
31972802 2020
18
Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes. 61
32037749 2020
19
Correction to: Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review. 61
32034688 2020
20
Evidence-based practice versus economics in treatment of macular edema secondary to central retinal vein occlusion in India. 61
31767969 2020
21
Optimization of diabetic macular edema management in the real-world: a model of excellence in retina units. The EMUREX initiative. 61
32015240 2020
22
Clinical findings and outcomes of uveitis associated with multiple sclerosis. 61
32019337 2020
23
COMPARISON OF LONG-TERM AUTOMATED RETINAL LAYER SEGMENTATION ANALYSIS OF MACULA BETWEEN SILICONE AND GAS TAMPONADE AFTER VITRECTOMY FOR RHEGMATOGENOUS RETINAL DETACHMENT. 61
32036367 2020
24
Resolution of optic disc pit-associated macular retinoschisis after topical carbonic anhydrase inhibitor treatment: Report of a case. 61
32019335 2020
25
Effect of Optical Coherence Tomography Patterns on One-year Outcomes of Aflibercept Therapy for Diabetic Macular Edema. 61
32036821 2020
26
Early and Late Switch from Ranibizumab to an Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema in the Event of a Poor Anatomical Response. 61
31768784 2020
27
Response of Retinal Sensitivity to Intravitreal Anti-angiogenic Bevacizumab and Triamcinolone Acetonide for Patients with Diabetic Macular Edema over One Year. 61
31961224 2020
28
Ophthalmology Retina Enters Year 4: Some Comments on Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. 61
31902470 2020
29
NOD-like Receptors in the Eye: Uncovering Its Role in Diabetic Retinopathy. 61
32019187 2020
30
Knowledge and practices of fundoscopy among general practitioners in Qassim Province, Saudi Arabia, for the management of diabetic retinopathy and diabetic macular edema: A cross-sectional study. 61
32002183 2020
31
Current concepts of pharmacotherapy of diabetic macular edema. 61
31957495 2020
32
AOCT-NET: a convolutional network automated classification of multiclass retinal diseases using spectral-domain optical coherence tomography images. 61
31728935 2020
33
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN PATIENTS WITH RETINITIS PIGMENTOSA-ASSOCIATED CYSTOID MACULAR EDEMA. 61
31923123 2020
34
Treatment of Capillary Hemangioblastoma in Von Hippel-Lindau Disease: Case Report and Online Survey of Treatment Preferences among Experts. 61
32009936 2020
35
The associations of objectively measured sleep duration and sleep disturbances with diabetic retinopathy. 61
31805348 2020
36
Familial autosomal recessive bestrophinopathy: identification of a novel variant in BEST1 gene and the specific metabolomic profile. 61
31969119 2020
37
Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases. 61
31364025 2020
38
Exploiting Epistemic Uncertainty of Anatomy Segmentation for Anomaly Detection in Retinal OCT. 61
31170065 2020
39
Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy. 61
31999300 2020
40
Do Genomic Factors Play a Role in Diabetic Retinopathy? 61
31947513 2020
41
COMBINED VITRECTOMY WITH INTRAVITREAL DEXAMETHASONE IMPLANT FOR REFRACTORY MACULAR EDEMA SECONDARY TO DIABETIC RETINOPATHY, RETINAL VEIN OCCLUSION, AND NONINFECTIOUS POSTERIOR UVEITIS. 61
30312262 2020
42
Classifications of diabetic macular edema. 61
31771348 2020
43
Multimodal Imaging Characteristics of a Large Retinal Capillary Macroaneurysm in an Eye With Severe Diabetic Macular Edema: A Case Presentation and Literature Review. 61
31976341 2020
44
EFFECTIVENESS OF EN BLOC REMOVAL OF FIBRINOGEN-RICH COMPONENT OF CYSTOID LESION FOR THE TREATMENT OF CYSTOID MACULAR EDEMA. 61
30334924 2020
45
Comparison of Retinal Layer Thickness in Eyes with Resolved Diabetic Macular Edema Receiving Ranibizumab with Normal Eyes. 61
31747663 2020
46
Correlation of multicolor images and conventional color fundus photographs with foveal autofluorescence patterns in diabetic macular edema. 61
31856492 2020
47
Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion. 61
31923032 2020
48
Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion. 61
31990746 2020
49
Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study. 61
31894377 2020
50
Quantitative Ultra-Widefield Angiographic Features and Associations with Diabetic Macular Edema. 61
31690541 2020

Variations for Macular Retinal Edema

Expression for Macular Retinal Edema

Search GEO for disease gene expression data for Macular Retinal Edema.

Pathways for Macular Retinal Edema

Pathways related to Macular Retinal Edema according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 VEGFB VEGFA TNF PGF KDR IL6
2
Show member pathways
13.49 VEGFB VEGFA TNF PGF KDR INS
3
Show member pathways
13.43 VEGFB TNF PGF KDR IL6 FLT1
4
Show member pathways
13.32 VEGFB TNF TJP1 PGF KDR IL6
5
Show member pathways
13.3 VEGFB VEGFA TNF PGF KDR IL6
6
Show member pathways
13.06 VEGFB PGF KDR INS IL6 FLT1
7
Show member pathways
12.96 VEGFA TNF IL6 ICAM1 CXCL8 CCL2
8
Show member pathways
12.96 VEGFB VEGFA TNF PGF KDR INS
9
Show member pathways
12.88 VEGFA TNF INS IL6 ICAM1 CXCL8
10
Show member pathways
12.84 TNF PLG IL6 ICAM1 CXCL8 CCL2
11 12.77 VEGFB VEGFA TNF PGF KDR INS
12
Show member pathways
12.76 VEGFB VEGFA PGF KDR INS FLT1
13
Show member pathways
12.73 VEGFB TNF PGF KDR IL6 FLT1
14
Show member pathways
12.68 VEGFA TJP1 OCLN KDR ICAM1 CCL2
15
Show member pathways
12.45 VEGFB VEGFA PGF KDR FLT1
16
Show member pathways
12.42 VEGFB PGF KDR IL6 FLT1
17
Show member pathways
12.41 VEGFA KDR ICAM1 CCL2
18
Show member pathways
12.35 TNF IL6 CXCL8 CCL2
19
Show member pathways
12.35 TNF IL6 CXCL8 CCL2
20 12.33 TNF TJP1 OCLN IL6 CXCL8
21 12.26 TNF IL6 CXCL8 CCL2
22
Show member pathways
12.26 VEGFB VEGFA KDR FLT1
23
Show member pathways
12.23 VEGFB TNF PGF KDR IL6 FLT1
24 12.2 VEGFA TNF IL6 CXCL8
25 12.13 VEGFA TNF KDR ICAM1 CCL2
26
Show member pathways
12.13 TNF PLG INS IL6 ICAM1 CCL2
27 12.09 VEGFA KDR INS IL6 ALB
28 12.05 TNF IL6 CXCL8 CCL2
29 12.01 TNF IL6 ICAM1 CXCL8 CCL2
30 12 TNF IL6 ICAM1 CCL2
31 11.99 VEGFA INS IL6 FLT1
32 11.89 VEGFB KDR FLT1 CCL2
33
Show member pathways
11.86 VEGFB VEGFA PGF KDR FLT1
34 11.86 VEGFA TNF IL6 ICAM1 CXCL8 CCL2
35 11.8 TJP1 IL6 CXCL8
36 11.78 TNF IL6 CXCL8
37 11.75 TNF IL6 CCL2
38 11.71 TNF IL6 CXCL8 CCL2
39 11.64 TNF IL6 CXCL8
40
Show member pathways
11.63 VEGFA TNF IL6 ICAM1 CXCL8
41 11.62 INS IL6 CXCL8
42 11.58 VEGFA IL6 CXCL8
43 11.57 TNF PLG IL6 ICAM1
44 11.56 VEGFA PLG KDR
45 11.55 VEGFA INS IL6
46 11.5 TNF IL6 ICAM1 CXCL8 CCL2
47 11.5 VEGFB VEGFA TNF IL6 ICAM1 CXCL8
48
Show member pathways
11.48 VEGFA KDR INS
49 11.48 VEGFB VEGFA KDR FLT1
50 11.46 TNF IL6 ICAM1 CXCL8 CCL2

GO Terms for Macular Retinal Edema

Cellular components related to Macular Retinal Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 VEGFB VEGFA TNF PLG PGF KDR
2 platelet alpha granule lumen GO:0031093 9.46 VEGFB VEGFA PLG ALB
3 extracellular space GO:0005615 9.44 VEGFB VEGFA TNF PLG PGF INS

Biological processes related to Macular Retinal Edema according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.03 VEGFA PGF KDR INS IL6 FLT1
2 cellular protein metabolic process GO:0044267 9.97 PLG INS IL6 ALB
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 TNF KDR ICAM1 CCL2
4 regulation of cell shape GO:0008360 9.92 VEGFA KDR ICAM1 CCL2
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 TNF INS IL6 ICAM1
6 cytokine-mediated signaling pathway GO:0019221 9.91 VEGFA TNF IL6 ICAM1 CXCL8 CCL2
7 positive regulation of protein phosphorylation GO:0001934 9.89 VEGFB VEGFA TNF PGF KDR
8 cellular response to tumor necrosis factor GO:0071356 9.88 OCLN ICAM1 CXCL8 CCL2
9 cellular response to lipopolysaccharide GO:0071222 9.88 TNF IL6 ICAM1 CXCL8 CCL2
10 platelet degranulation GO:0002576 9.85 VEGFB VEGFA PLG ALB
11 response to hypoxia GO:0001666 9.85 VEGFB VEGFA PGF KCNMA1 ICAM1
12 positive regulation of angiogenesis GO:0045766 9.85 VEGFB VEGFA PGF KDR FLT1 CXCL8
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 VEGFA TNF IL6
14 positive regulation of MAPK cascade GO:0043410 9.84 KDR INS IL6 FLT1
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 TNF KDR INS FLT1
16 positive regulation of MAP kinase activity GO:0043406 9.82 VEGFA TNF FLT1
17 humoral immune response GO:0006959 9.82 TNF IL6 CCL2
18 positive chemotaxis GO:0050918 9.81 VEGFB VEGFA PGF
19 positive regulation of endothelial cell proliferation GO:0001938 9.81 VEGFB VEGFA PGF KDR
20 positive regulation of cell division GO:0051781 9.8 VEGFB VEGFA PGF
21 angiogenesis GO:0001525 9.8 VEGFB VEGFA PGF KDR FLT1 CXCL8
22 monocyte chemotaxis GO:0002548 9.79 IL6 FLT1 CCL2
23 protein kinase B signaling GO:0043491 9.77 TNF KDR CCL2
24 ovarian follicle development GO:0001541 9.75 VEGFA ICAM1 FANCG
25 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.74 VEGFA KDR FLT1
26 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.72 VEGFB VEGFA PGF KDR FLT1
27 negative regulation of lipid storage GO:0010888 9.66 TNF IL6
28 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.65 VEGFA PLG
29 neutrophil mediated immunity GO:0002446 9.65 IL6 ACE
30 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.63 VEGFA KDR
31 negative regulation of protein oligomerization GO:0032460 9.63 INS ALB
32 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.6 VEGFA ACE
33 positive regulation of mast cell chemotaxis GO:0060754 9.58 VEGFB VEGFA PGF
34 induction of positive chemotaxis GO:0050930 9.46 VEGFB VEGFA PGF CXCL8
35 sprouting angiogenesis GO:0002040 9.35 VEGFB VEGFA PGF KDR FLT1
36 vascular endothelial growth factor signaling pathway GO:0038084 9.02 VEGFB VEGFA PGF KDR FLT1

Molecular functions related to Macular Retinal Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.13 VEGFB VEGFA TNF TJP1 PLG PGF
2 growth factor activity GO:0008083 9.67 VEGFB VEGFA PGF IL6
3 chemoattractant activity GO:0042056 9.5 VEGFB VEGFA PGF
4 vascular endothelial growth factor binding GO:0038085 9.43 KDR FLT1
5 vascular endothelial growth factor-activated receptor activity GO:0005021 9.4 KDR FLT1
6 cytokine activity GO:0005125 9.35 VEGFA TNF IL6 CXCL8 CCL2
7 vascular endothelial growth factor receptor 1 binding GO:0043183 9.26 VEGFB VEGFA
8 vascular endothelial growth factor receptor binding GO:0005172 8.8 VEGFB VEGFA PGF

Sources for Macular Retinal Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....